{
    "clinical_study": {
        "@rank": "104053", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "Desipramine Arm"
        }, 
        "brief_summary": {
            "textblock": "Intrapatient dose escalation of desipramine. Start at 75 mg daily. Increase by 75 mg weekly\n      to maximum of 450 mg daily.  Taper desipramine upon disease progression, unacceptable\n      toxicity or patient withdrawal from study."
        }, 
        "brief_title": "Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma", 
                "Neuroendocrine Tumors"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objective:\n\n      To determine the overall response rate (ORR) of small cell lung cancer and high-grade\n      neuroendocrine tumors in patients during treatment with desipramine.\n\n      Secondary Objectives:\n\n        -  To determine the progression-free survival (PFS) and overall survival (OS).\n\n        -  To perform exploratory blood biomarker analysis of PCSK1 and ROBO1 in patients enrolled\n           on this trial.\n\n        -  To measure safety of desipramine using type, frequency and severity of adverse event\n           reactions reported according to CTCAE v4.0\n\n        -  To measure tolerability using the incidence of adverse events (AEs) leading to\n           desipramine delay or discontinuation\n\n        -  To establish the MTD of desipramine in each patient by adhering to an intrapatient dose\n           escalation schema\n\n        -  To measure serum desipramine levels during treatment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Metastatic small-cell lung cancer -or- Metastatic high-grade neuroendocrine carcinoma\n             of any organ system (high-grade defined by Ki-67 >= 20% and/or >= 20 mitoses/10\n             (HPF).\n\n          -  Received at least one line of prior chemotherapy treatment for metastatic disease.\n             After progression on first-line chemotherapy, disease does not have to have\n             progressed on subsequent lines of therapy to enroll on trial.\n\n          -  Completed previous treatment in greater than or equal to the following times prior to\n             initiation of study treatment:\n\n               -  Chemotherapy administered in a daily schedule must be completed >= 2 weeks prior\n                  to registration;\n\n               -  Chemotherapy administered in a weekly schedule must be completed >= 2 weeks\n                  prior to registration;\n\n               -  Chemotherapy administered in a 2-weekly schedule must be completed >= 3 weeks\n                  prior to registration;\n\n               -  Chemotherapy administered in a 3-weekly schedule must be completed >= 4 weeks\n                  prior to registration.\n\n          -  ECOG Performance Status 0-2\n\n          -  Measurable disease by RECIST 1.1 criteria\n\n          -  Age at least 18 years-old otherwise no age, gender/race-ethnic restrictions\n\n          -  At least 3 months estimated life expectancy.\n\n          -  Laboratory tests within the following parameters:\n\n               -  Absolute neutrophil count >= 1,500/ mm3\n\n               -  Platelets >= 100,000/mm3\n\n               -  Hemoglobin >= 9 g/Dl\n\n               -  Total bilirubin <= 1.5 mg/dL\n\n               -  AST(SGOT) and ALT(SGPT) <= 3 X ULN (Stanford: AST(SGOT) ULN 60, ALT (SGPT) ULN\n                  80).\n\n               -  Creatinine <=1.5 X ULN (Stanford: ULN 1.1) -or- Calculated (See Appendix F for\n                  Cockgroft-Gault formula) measured creatinine clearance >= 45 mL/min/1.73m2\n                  (normalized to BSA) for patients with creatinine levels above institutional\n                  normal\n\n          -  ECG demonstrating all of the following:\n\n               -  QT interval corrected using Fridericia's method (QTcF) <450 msec (males) or <470\n                  msec (females) (see Appendix E for Fredericia's criteria).\n\n               -  PR <240 msec\n\n               -  QRS <100 msec\n\n          -  Brain metastases are allowed, but must be asymptomatic and have been adequately\n             treated with radiation finishing at least 1 week prior to initiation of study\n             treatment.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Cardiac disorders including the following:\n\n               -  Clinically significant ventricular arrhythmia including cardiac arrest\n\n               -  Myocardial infarction from coronary artery disease within 3 months of study\n                  enrollment\n\n               -  Implantable pacemaker or implantable cardioverter defibrillator\n\n               -  NYHA Class III or greater congestive heart failure\n\n          -  Family history of long QT syndrome.\n\n          -  Concomitant or expected treatment with any of the following prohibited study\n             medications. Any prohibited drugs must be discontinued at least 2 weeks or 5-half\n             lives prior to the initiation of desipramine, whichever is shortest (except\n             fluoxetine, because of long half life, will need a at least a 5 week washout period).\n             (see appendix C and D for lists of prohibited drugs)\n\n          -  Medications that prolong the QT interval and are known to increase risk of torsades\n             de pointes (see appendix D for excluded drugs)\n\n          -  Strong inhibitors of cytochrome p450 CYP2D6 (see appendix C)\n\n          -  Other anti-depressant or anti-psychotic including a SSRI, other tricyclic, MAOI,\n             SNRI, typical or atypical anti-psychotic\n\n          -  Metoclopramide (Reglan) because of increased risk of Extrapyrimidal Symptoms and\n             Neuroleptic Malignant Syndrome\n\n          -  Symptomatic orthostatic hypotension despite adequate volume resuscitation.\n\n          -  Medical history of narrow angle glaucoma\n\n          -  Any of the following known psychiatric conditions, diagnosed by a psychiatrist,\n             either ongoing or active within the last 5 years:\n\n               -  Bipolar disorder\n\n               -  Suicidal ideation\n\n               -  Suicide attempt\n\n          -  Patients who are pregnant or breastfeeding. Female subjects of childbearing potential\n             must have a negative pregnancy test prior to enrollment and practice acceptable\n             methods of birth control to avoid pregnancy. Male subjects must also practice\n             acceptable methods of birth control to prevent pregnancy of a partner.\n\n          -  No other Investigational Agents allowed while on this trial.\n\n          -  Any other serious or unstable concomitant systemic disorder that in the opinion of\n             the investigator is incompatible with the clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719861", 
            "org_study_id": "VAR0087", 
            "secondary_id": "25491"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "intervention_name": "desipramine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Desipramine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIa Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors", 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Joel Neal", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Overall Response Rate (ORR): Number of patients who achieve either a partial or complete response divided by the total number of patients treated on the study as measured by CT scans and RECIST 1.1 criteria.", 
            "safety_issue": "No", 
            "time_frame": "At baseline and every 8 weeks up to 3 years."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719861"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Joel Neal", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Joel Neal", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Lack of efficacy"
    }
}